What's bigger than a unicorn? Samumed stuns yet again as anti-aging pipeline draws $438M at $12B valuation
Samumed came out with a bang a couple years ago, when it boldly announced a couple of anti-aging programs and a $12 billion valuation. The San Diego company, which operated in stealth through much of its first decade, had no late-stage programs and no products on the market at the time, causing quite the hubbub when it claimed unicorn status.
Today, that company has added $438 million of equity backing to its coffers, closing a mega-round that adds to its previously raised $212 million. And yet again, the company announced its pre-money valuation for the latest round at a whopping $12 billion. Even in these go-go days of biotech, the dollars are eye-popping.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.